Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-05-04Clinical Trial Update: Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies [Phase 2, Phase 3]
A phase 2/3 trial evaluating non-myeloablative allogeneic HSCT from HLA-matched related or unrelated donors in low-grade B-cell malignancies…
-
CLINICAL_TRIALS trial_result · 2017-04-11Clinical Trial Update: Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies [Phase 1]
A Phase 1 clinical trial update reports the completion of a study evaluating intravenously administered SNS-032 in patients with advanced B-…
-
CLINICAL_TRIALS trial_result · 2017-04-07Clinical Trial Update: Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating lenalidomide plus rituximab in previously untreated mantle cell lymphoma; results have been posted.
-
CLINICAL_TRIALS trial_result · 2017-04-07Clinical Trial Update: Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL [Phase 1, Phase 2]
Phase I/II study evaluating Velcade (bortezomib) added to CHOP-Rituximab in untreated diffuse large B-cell lymphoma and mantle cell lymphoma…
-
CLINICAL_TRIALS trial_result · 2017-03-31Clinical Trial Update: Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies [NA]
A terminated clinical trial evaluated mobilizing donor peripheral blood stem cells with plerixafor and filgrastim before donor transplant in…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-03-10Clinical Trial Update: Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients [Phase 1]
Phase 1 clinical trial update of an anti-CD22 CAR-T therapy for CD19-refractory or resistant lymphomas, including diffuse large B-cell lymph…
-
CLINICAL_TRIALS trial_result · 2017-03-09Clinical Trial Update: Tandem Auto-Allo Transplant for Lymphoma [Phase 2]
Phase 2 clinical trial update on tandem auto-allo transplantation for various lymphomas, with completed status and results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-03-09Clinical Trial Update: Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL). [Phase 1, Phase 2]
A phase 1/2 study evaluating escalating doses of temsirolimus (Torisel) in combination with R-CHOP, R-FC, or R-DHA regimens in patients with…
-
CLINICAL_TRIALS trial_result · 2017-03-07Clinical Trial Update: Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL [Phase 3]
This clinical trial update reports on the efficacy and safety of the Rituximab-based R-HAD regimen alone or in combination with Bortezomib i…
-
CLINICAL_TRIALS trial_result · 2017-03-01Clinical Trial Update: Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy [Phase 3]
Phase 3 trial comparing ibrutinib versus temsirolimus in relapsed/refractory mantle cell lymphoma; results completed with results posted in …
-
CLINICAL_TRIALS trial_result · 2017-02-28Clinical Trial Update: CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy [Phase 1]
Phase 1 trial evaluating CART19 therapy for B-cell hematologic malignancies including various lymphomas and leukemias that are refractory or…
-
CLINICAL_TRIALS trial_result · 2017-02-16Clinical Trial Update: Observational Study for Patients With Newly Diagnosed (MCL) Not Eligible for High-dose Therapy
This update notes the completion of an observational study evaluating patients with newly diagnosed Mantle Cell Lymphoma who are not eligibl…
-
CLINICAL_TRIALS trial_result · 2017-02-15Clinical Trial Update: CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant [Phase 1, Phase 2]
This update covers a phase 1/2 clinical trial evaluating CD19 CAR T cells for B-cell malignancies in patients after allogeneic transplantati…
-
CLINICAL_TRIALS trial_result · 2017-02-09Clinical Trial Update: AMG 319 Lymphoid Malignancy FIH [Phase 1]
First-in-human Phase 1 clinical trial update for AMG 319 in lymphoid malignancies, including chronic lymphocytic leukemia and various lympho…
-
CLINICAL_TRIALS trial_result · 2017-01-31Clinical Trial Update: Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2017-01-27Clinical Trial Update: Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial evaluating a conditioning regimen with Iodine-131 tositumomab plus etoposide and cyclophosphamide, followed by autolo…
-
CLINICAL_TRIALS trial_result · 2017-01-26Clinical Trial Update: Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
This ClinicalTrials.gov update reports on an observational study evaluating lenalidomide in patients with mantle cell lymphoma who failed ib…
-
CLINICAL_TRIALS trial_result · 2017-01-24Clinical Trial Update: Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
This update reports results from a phase 2 study of the BTK inhibitor ibrutinib in participants with relapsed or refractory mantle cell lymp…
-
CLINICAL_TRIALS trial_result · 2017-01-12Clinical Trial Update: Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma [Phase 2]
Phase 2 trial in Mantle Cell Lymphoma evaluating two Rituximab-based regimens (Rituximab/Bendamustine and Rituximab/Cytarabine); results wer…
-
CLINICAL_TRIALS trial_result · 2017-01-11Clinical Trial Update: The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating the efficacy and safety of combining bortezomib with fludarabine and cytarabine in mantle cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2016-12-23Clinical Trial Update: Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 study evaluating a combination of bortezomib, rituximab, and yttrium-90 ibritumomab tiuxetan in relapsed or refractory low-grade, fo…
-
CLINICAL_TRIALS trial_result · 2016-12-22Clinical Trial Update: A Phase II Study of Doxycycline in Relapsed NHL [Phase 2]
Phase II trial of doxycycline in relapsed non-Hodgkin lymphoma was terminated and results were posted in 2016.
-
CLINICAL_TRIALS trial_result · 2016-12-07Clinical Trial Update: Cladribine in Patients With Mantle Cell Lymphoma [Phase 2]
Phase 2 trial evaluating cladribine in mantle cell lymphoma has completed. Sponsored by the Alliance for Clinical Trials in Oncology.
-
CLINICAL_TRIALS trial_result · 2016-12-06Clinical Trial Update: PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma [Phase 1, Phase 2]
Clinical trial update describing the evaluation of PCAR-119 Bridge Immunotherapy as a pre-transplant treatment for CD19-positive leukemias a…
-
CLINICAL_TRIALS trial_result · 2016-11-03Clinical Trial Update: Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell [Phase 2]
Phase 2 trial evaluating a combination of gemcitabine, mitoxantrone (Novantrone), and rituximab for relapsed or refractory mantle cell lymph…